uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2025-32-1-31-42uzspbgmu-1114Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESАспекты лечения пациентов с абдоминальной онкопатологией на фоне хронической болезни почекAspects of treatment of patients with abdominal oncopathology against the background of chronic kidney diseasehttps://orcid.org/0000-0002-5153-2061ПалтышевИ. А.PaltyshevI. A.

Палтышев Илья Александрович, кандидат медицинских наук, врач-онколог онкологического отделения № 1, руководитель отделения детской хирургии НИИ хирургии и неотложной медицины, доцент кафедры онкологии ФПО

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Paltyshev Ilya A., Cand. of Sci. (Med.), Oncologist of the Oncological Department №1, Head of the Department of Pediatric Surgery of the Research Institute of Surgery and Emergency Medicine, Associate Professor of the Department of Oncology of the Faculty of Postgraduate Education

6-8, L’va Tolstogo str., Saint Petersburg, 197022

Eexss@mail.ruhttps://orcid.org/0000-0003-0830-3797БеляевМ. А.BelyaevM. A.

Беляев Михаил Алексеевич, кандидат медицинских наук, научный сотрудник, руководитель отделения абдоминальной онкологии, зам. главного врача клиники по онкологии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Belyaev Mikhail A., Cand. of Sci. (Med.), Research Fellow, Head of the Department of Abdominal Oncology, Deputy Chief Physician of Oncology Clinic

6-8, L’va Tolstogo str., Saint Petersburg, 197022

https://orcid.org/0000-0002-8514-5377ЗахаренкоА. А.ZakharenkoA. A.

Захаренко Александр Анатольевич, доктор медицинских наук, профессор, зав. кафедрой онкологии ФПО

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Zakharenko Aleksandr A., Dr. of Sci. (Med.), Professor, Head of the Department of Oncology of the Faculty of Postgraduate Education

6-8, L’va Tolstogo str., Saint Petersburg, 197022

Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. ПавловаРоссияPavlov UniversityRussian Federation2025070620253213142Copyright © Палтышев И.А., Беляев М.А., Захаренко А.А., 20252025Палтышев И.А., Беляев М.А., Захаренко А.А.Paltyshev I.A., Belyaev M.A., Zakharenko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/1114

Онконефрология – раздел медицинской науки, находящийся на стыке специальностей (онкология и нефрология), которая занимается аспектами заболеваний почек, возникших на фоне лечения онкологических заболеваний, а также течением онкологического процесса на фоне ранее выявленной хронической болезни почки (ХБП). Обзор литературы освещает отдельные проблемы, связанных с лечением онкологических больных на фоне дисфункции почек: эпидемиологию, особенности проведения диагностических и динамических обследований, проведение хирургического и химиотерапевтического лечения, а также ряд организационных проблем, которые возникают при планировании лечения этой сложной группы.

Onconephrology is a branch of medical science located at the junction of specialties (oncology and nephrology), which deals with aspects of kidney diseases that have arisen against the background of cancer treatment, as well as the course of the oncological process against the background of previously identified chronic kidney disease (CKD). The literature review highlights some problems related to the treatment of cancer patients with kidney dysfunction: epidemiology, features of diagnostic and dynamic examinations, surgical and chemotherapeutic treatment, as well as a number of organizational problems that arise when planning treatment for this complex group.

хроническая болезнь почкигемодиализпочечная недостаточностьракхимиотерапияchronic kidney diseasehemodialysiskidney failurecancerchemotherapyАвторы выражают благодарность в редактировании текста и консультативной работе с материалом директору клиники НИИ нефрологии ФГБОУ ВО ПСПбГМУ им. И. П. Павлова доктору медицинских наук, профессору Добронравову Владимиру Александровичу.The authors express their gratitude in the editing of the text and consultative work with material to the Director of the Clinic of the Research Institute of Neurology of the Pavlov University, Doctor of medical sciences, Professor Dobronravov Vladimir Aleksandrovich.ReferencesLam A. Q., Humphreys B. D. Onco-nephrology: AKI in the cancer patient // Clinical journal of the American Society of Nephrology: CJASN. – 2012. – Vol. 7, № 10. – P. 1692–1700. https://doi.org/10.2215/CJN.03140312.Lam A. Q., Humphreys B. D. Onco-nephrology: AKI in the cancer patient // Clinical journal of the American Society of Nephrology: CJASN. 2012;7(10):1692–1700. https://doi.org/10.2215/CJN.03140312.de Francisco A. L. M., Macía M., Alonso F. et al. Onco-Nephrology: Cancer, chemotherapy and kidney // Nefrologia (Engl Ed). – 2019. – Vol. 39, № 5. – P. 473–481. (English, Spanish). https://doi.org/10.1016/j.nefro.2018.10.016. PMID: 30929891.de Francisco A. L. M., Macía M., Alonso F. et al. Onco-Nephrology: Cancer, chemotherapy and kidney // Nefrologia (Engl Ed). 2019;39(5):473–481. (English, Spanish). https://doi.org/10.1016/j.nefro.2018.10.016. PMID: 30929891.Shirazian S., Starakiewicz P., Latcha S. Cancer Screening in End-Stage Kidney Disease // Adv Chronic Kidney Dis. – 2021. – Vol. 28, № 5. – P. 502–508.e1. https://doi.org/10.1053/j.ackd.2021.09.006. PMID: 35190116.Shirazian S., Starakiewicz P., Latcha S. Cancer Screening in End-Stage Kidney Disease // Adv Chronic Kidney Dis. 2021;28(5):502–508.e1. https://doi.org/10.1053/j.ackd.2021.09.006. PMID: 35190116.Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018. – P. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: a cancer journal for clinicians. – 2018. – Vol. 68, № 6. – P. 394–424. https://doi.org/10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: a cancer journal for clinicians. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.Шахзадова А. О., Старинский В. В., Лисичникова И. В. Состояние онкологической помощи населению России в 2022 году // Сибирский онкологический журнал. – 2023. – Т. 22, № 5. – С. 5–13. https://doi.org/10.21294/1814-4861-2023-22-5-5-13.Shakhzadova A. O., Starinsky V. V., Lisichnikova I. V. Cancer care to the population of Russia in 2022 // Siberian journal of oncology. 2023;22(5):5–13. (In Russ.). https://doi.org/10.21294/1814-4861-2023-22-5-5-13.Lv J. C., Zhang L. X. Prevalence and Disease Burden of Chronic Kidney Disease // Adv Exp Med Biol. – 2019. – Vol. 1165. – P. 3–15. https://doi.org/10.1007/978-981-13-8871-2_1. PMID: 31399958.Lv J. C., Zhang L. X. Prevalence and Disease Burden of Chronic Kidney Disease // Adv Exp Med Biol. 2019;1165:3–15. https://doi.org/10.1007/978-981-13-8871-2_1. PMID: 31399958.Румянцева Е. И. Хроническая болезнь почек как глобальная проблема для общественного здоровья: динамика заболеваемости и смертности // Проблемы стандартизации в здравоохранении. – 2021. – Т. 1–2. – С. 41–49. https://doi.org/10.26347/1607-2502202101-02041-049.Rumyantseva E. I. Chronic kidney disease as a global public health problem: trends in morbidity and mortality // Health Care Standardization Problems. 2021;1–2:41–49. https://doi.org/10.26347/1607-2502202101-02041-049.Rosner M. H., Jhaveri K. D., McMahon B. A., Perazella M. A. Onconephrology: The intersections between the kidney and cancer // CA Cancer J Clin. – 2021. – Vol. 71, № 1. – P. 47–77. https://doi.org/10.3322/caac.21636. PMID: 32853404.Rosner M. H., Jhaveri K. D., McMahon B. A., Perazella M. A. Onconephrology: The intersections between the kidney and cancer // CA Cancer J Clin. 2021;71(1):47–77. https://doi.org/10.3322/caac.21636. PMID: 32853404.Коваленко Н. В., Иванов А. И., Галеев Ш. Р. и др. Хирургическое лечение злокачественной опухоли желудка у пациента с хронической болезнью почек на программном гемодиализе // Креативная хирургия и онкология. – 2021. – Т. 11, № 4. – С. 337–342. https://doi.org/10.24060/2076-3093-2021-11-4-337-342.Kovalenko N. V., Ivanov A. I., Galeev S. R. et al. Surgical Treatment of Gastric Malignancy in Chronic Kidney Disease Patient with Long-Term Haemodialysis // Creative surgery and oncology. 2021;11(4):337–342. (In Russ.). https://doi.org/10.24060/2076-3093-2021-11-4-337-342.Джумабаева Б. Т., Бирюкова Л. С. Нефротоксичность противоопухолевых препаратов, коррекция их дозы при лечении больных лимфопролиферативными и онкологическими заболеваниями, ассоциированными с почечной недостаточностью // Гематология и трансфузиология. – 2015. – Т. 60, № 4. – С. 30–35.Dzhumabaeva B. T., Biryukova L. S. Nephrotoxicity of antitumor drugs and correction of their doses in therapy of patients with lymphomas and cancer associated with renal failure // Hematology and transfusiology (Gematologiya i transfuziologiya). 2015;60(4):30–35. (In Russ.).Hu M., Wang Q., Liu B. et al. Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms // Front. Cell Dev. Biol. – 2022. – Vol. 10. – P. 868715.Hu M., Wang Q., Liu B. et al. Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms // Front. Cell Dev. Biol. 2022;10:868715.Ciorcan M., Chisavu L., Mihaescu A. et al. Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe // PLoS ONE. – 2022. – Vol. 17. – P. e0265930.Ciorcan M., Chisavu L., Mihaescu A. et al. Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe // PLoS ONE. 2022;17:e0265930.Plaisier E., Ronco P. Screening for Cancer in Patients with Glomerular Diseases // Clin. J. Am. Soc. Nephrol. – 2020. – Vol. 15. – P. 886–888.Plaisier E., Ronco P. Screening for Cancer in Patients with Glomerular Diseases // Clin. J. Am. Soc. Nephrol. 2020;15:886–888.Rosner M. H., Jhaveri K. D., McMahon B. A., Perazella M. A. Onconephrology: The intersections between the kidney and cancer // CA Cancer J. Clin. – 2021. – Vol. 71. – P. 47–77.Rosner M. H., Jhaveri K. D., McMahon B. A., Perazella M. A. Onconephrology: The intersections between the kidney and cancer // CA Cancer J. Clin. 2021;71:47–77.Matas A. J., Simmons R. L., Kjellstrand C. M. et al. Increased incidence of malignancy during chronic renal failure // Lancet (London, England). – 1975. – Vol. 1, № 7912. – P. 883–886. https://doi.org/10.1016/s0140-6736(75)91684-0.Matas A. J., Simmons R. L., Kjellstrand C. M. et al. Increased incidence of malignancy during chronic renal failure // Lancet (London, England). 1975;1(7912):883–886. https://doi.org/10.1016/s0140-6736(75)91684-0.Volovat S. R., Volovat C., Miron I. et al. Oncogenic mechanisms in renal insufficiency // Clin Kidney J. – 2020. – Vol. 14, № 2. – P. 507–515. https://doi.org/10.1093/ckj/sfaa122. PMID: 33623673; PMCID: PMC7886561.Volovat S. R., Volovat C., Miron I. et al. Oncogenic mechanisms in renal insufficiency // Clin Kidney J. 2020;14(2):507–515. https://doi.org/10.1093/ckj/sfaa122. PMID: 33623673; PMCID: PMC7886561.Park S., Lee S., Kim Y. et al. Risk of cancer in pre-dialysis chronic kidney disease: A nationwide population-based study with a matched control group // Kidney research and clinical practice. – 2019. – Vol. 38, № 1. – P. 60–70. https://doi.org/10.23876/j.krcp.18.0131.Park S., Lee S., Kim Y. et al. Risk of cancer in pre-dialysis chronic kidney disease: A nationwide population-based study with a matched control group // Kidney research and clinical practice. 2019;38(1):60–70. https://doi.org/10.23876/j.krcp.18.0131.Oh H. J., Lee H. A., Moon C. et al. The Combined Impact of Chronic Kidney Disease and Diabetes on the Risk of Colorectal Cancer Depends on Sex: A Nationwide Population-Based Study // Yonsei medical journal. – 2020. – Vol. 61, № 6. – P. 506–514. https://doi.org/10.3349/ymj.2020.61.6.506.Oh H. J., Lee H. A., Moon C. et al. The Combined Impact of Chronic Kidney Disease and Diabetes on the Risk of Colorectal Cancer Depends on Sex: A Nationwide Population-Based Study // Yonsei medical journal. 2020;61(6):506–514. https://doi.org/10.3349/ymj.2020.61.6.506.Абрамова Е. Э., Королева И. Е., Тов Н. Л. и др. Факторы риска летальных исходов у больных на гемодиализе // Journal of Siberian Medical Sciences. – 2015. – № 6. – С. 15–26.Abramova E. E., Koroleva I. E., Tov N. L. et al. Risk factors of lethal outcomes at patients on hemodialysis // Journal of Siberian Medical Sciences. 2015;(6):15.Vajdic C. M., McDonald S. P., McCredie M. R. et al. Cancer incidence before and after kidney transplantation // JAMA. – 2006. – Vol. 296, № 23. – P. 2823–2831. https://doi.org/10.1001/jama.296.23.2823.Vajdic C. M., McDonald S. P., McCredie M. R. et al. Cancer incidence before and after kidney transplantation // JAMA. 2006;296(23):2823–2831. https://doi.org/10.1001/jama.296.23.2823.Nabi Z., Zahid T., Nabi R. Post Renal Transplant Malignancies: A Basic Concept // J Ayub Med Coll Abbottabad. – 2023. – Vol. 35, № 4. – P. 664–668. https://doi.org/10.55519/JAMC-04-12230. PMID: 38406957.Nabi Z., Zahid T., Nabi R. Post Renal Transplant Malignancies; A Basic Concept // J Ayub Med Coll Abbottabad. 2023;35(4):664–668. https://doi.org/10.55519/JAMC-04-12230. PMID: 38406957.Komaki Y., Komaki F., Micic D. et al. Risk of Colorectal Cancer in Chronic Kidney Disease. – P. A Systematic Review and Meta-Analysis // J Clin Gastroenterol. –2018. – Vol. 52, № 9. – P. 796–804. https://doi.org/10.1097/MCG.0000000000000880. PMID: 28723862.Komaki Y., Komaki F., Micic D. et al. Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis // J Clin Gastroenterol. 2018;52(9):796–804. https://doi.org/10.1097/MCG.0000000000000880. PMID: 28723862.Нейроэндокринные опухоли. Клинические рекомендации. URL: https://oncology-association.ru/clinical-guidelines (дата обращения: 01.04.2025).Neuroendocrine tumors. Clinical guidelines. URL: https://oncology-association.ru/clinical-guideline (accessed: 01.04.2025).Coppolino G., Bolignano D., Rivoli L. et al. Tumour markers and kidney function: a systematic review // Biomed Res Int. – 2014. – Vol. 2014. – P. 647541. https://doi.org/10.1155/2014/647541. PMID: 24689048; PMCID: PMC3933284.Coppolino G., Bolignano D., Rivoli L. et al. Tumour markers and kidney function: a systematic review // Biomed Res Int. 2014;2014:647541. https://doi.org/10.1155/2014/647541. PMID: 24689048; PMCID: PMC3933284.Lee Y. C., Hsieh C. C., Chang T. T. et al. Contrast-Induced Acute Kidney Injury Among Patients With Chronic Kidney Disease Undergoing Imaging Studies: A Meta-Analysis // AJR. American journal of roentgenology. – 2019. – Vol. 213, № 4. – P. 728–735. https://doi.org/10.2214/AJR.19.21309.Lee Y. C., Hsieh C. C., Chang T. T. et al. Contrast-Induced Acute Kidney Injury Among Patients With Chronic Kidney Disease Undergoing Imaging Studies: A Meta-Analysis // AJR. American journal of roentgenology. 2019;213(4):728–735. https://doi.org/10.2214/AJR.19.21309.Смирнов А. В., Добронравов В. А., Румянцев А. Ш. и др. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть I // Нефрология. – 2016. – Т. 20, № 1. – С. 79–104. https://doi.org/10.24884/1561-6274-2016-20-1-8-15.Smirnov A. V., Dobronravov V. A., Rumyantsev A. Sh. et al. National guidelines acute kidney injury: basic principles of diagnosis, prevention and therapy. Part I // Nephrology. 2016;20(1):79–104. (In Russ.). https://doi.org/10.24884/1561-6274-2016-20-1-8-15.Cosmai L., Porta C., Privitera C. et al. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies // ESMO Open. – 2020. – Vol. 5, № 2. – P. e000618. https://doi.org/10.1136/esmoopen-2019-000618. PMID: 32205339; PMCID: PMC7204797.Cosmai L., Porta C., Privitera C. et al. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies // ESMO Open. 2020;5(2):e000618. https://doi.org/10.1136/esmoopen-2019-000618. PMID: 32205339; PMCID: PMC7204797.Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. – 2021. – Vol. 25, № 5. – P. 10–82.Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10–82. (In Russ.).Barr R. G., Peterson C., Hindi A. Evaluation of indeterminate renal masseswith contrast-enhanced US: a diagnostic performance study // Radiology. – 2014. – Vol. 271, № 1. – P. 133–142.Barr R. G., Peterson C., Hindi A. Evaluation of indeterminate renal masseswith contrast-enhanced US: a diagnostic performance study // Radiology. 2014;271(1):133–142.Kazmierski B., Deurdulian C., Tchelepi H., Grant E. G. Applications of contrast-enhanced ultrasound in the kidney // Abdom Radiol (NY). – 2018. – Vol. 43, № 4. – P. 880–898.Kazmierski B., Deurdulian C., Tchelepi H., Grant E. G. Applications of contrast-enhanced ultrasound in the kidney // Abdom Radiol (NY). 2018;43(4):880–898.Barr R. G., Wilson S. R., Lyshchik A. et al. Contrast-enhanced Ultrasound-Stateof the Art in North America: Society of Radiologists in Ultrasound WhitePaper // Ultrasound Q. – 2020. – Vol. 36, № 4S Suppl 1. – P. S1–S39.Barr R. G., Wilson S. R., Lyshchik A. et al. Contrast-enhanced Ultrasound-Stateof the Art in North America: Society of Radiologists in Ultrasound WhitePaper // Ultrasound Q. 2020;36(4S Suppl 1):S1–S39.Kazmierski B. J., Sharbidre K. G., Robbin M. L., Grant E. G. Contrast-Enhanced Ultrasound for the Evaluation of Renal Transplants // J Ultrasound Med. – 2020. – Vol. 39, № 12. – P. 2457–2468.Kazmierski B. J., Sharbidre K. G., Robbin M. L., Grant E. G. Contrast-Enhanced Ultrasound for the Evaluation of Renal Transplants // J Ultrasound Med. 2020;39(12):2457–2468.Cantisani V., Bertolotto M., Clevert D. A. et al. EFSUMB 2020 Proposal fora Contrast-Enhanced Ultrasound-Adapted Bosniak Cyst Categorization – Position Statement // Ultraschall Med. – 2021. – Vol. 42, № 2. – P. 154–166.Cantisani V., Bertolotto M., Clevert D. A. et al. EFSUMB 2020 Proposal fora Contrast-Enhanced Ultrasound-Adapted Bosniak Cyst Categorization – Position Statement // Ultraschall Med. 2021;42(2):154–166.Петрова Е. Н., Полушин Ю. С., Шлык И. В., Цед А. Н. Особенности периоперационного ведения пациентов с терминальной стадией хронической болезни почек при эндопротезировании тазобедренного и коленного суставов // Альманах клинической медицины. – 2019. – Т. 47, № 3. – С. 251–265. https://doi.org/10.18786/2072-0505-2019-47-033.Petrova E. N., Polushin Yu. S., Shlyk I. V., Tsed A. N. Particulars of the perioperative management of patients with end stage renal disease during hip and knee replacement arthroplasty // Almanac of Clinical Medicine. 2019;47(3):251–265. (In Russ.). https://doi.org/10.18786/2072-0505-2019-47-033.Li P. K., Szeto C. C., Piraino B. et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment // Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis. – 2016. – Vol. 36, № 5. – P. 481–508. https://doi.org/10.3747/pdi.2016.00078.Li P. K., Szeto C. C., Piraino B. et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment // Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2016;36(5):481–508. https://doi.org/10.3747/pdi.2016.00078.Okayama M., Inoue T., Nodaira Y. et al. Aging is an important risk factor for peritoneal dialysis-associated peritonitis // Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. – 2012. – Vol. 28. – P. 50–54.Okayama M., Inoue T., Nodaira Y. et al. Aging is an important risk factor for peritoneal dialysis-associated peritonitis // Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 2012;28:50–54.Громова Е. Г., Бирюкова Л. С., Джумабаева Б. Т., Курмуков И. А. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов // Злокачественные опухоли: Практические рекомендации RUSSCO. – 2022. – Т. 12, № 3s2. – С. 144–158.Gromova E. G., Biryukova L. S., Dzhumabaeva B. T., Kurmukov I. A. Practical recommendations for the correction of nephrotoxicity of antitumor drugs // Malignant Tumors: Practical Recommendations RUSSCO. 2022;12(3s2):144–158. (In Russ.). https://doi.org/10.18027/2224-5057-2022-12-3s2-144-158.Gweon T. G., Jung S. H., Kim S. W. et al. Risk factors for peritonitis in patients on continuous ambulatory peritoneal dialysis who undergo colonoscopy: a retrospective multicentre study // BMC gastroenterology. – 2019. – Vol. 19, № 1. – P. 175. https://doi.org/10.1186/s12876-019-1081-2.Gweon T. G., Jung S. H., Kim S. W. et al. Risk factors for peritonitis in patients on continuous ambulatory peritoneal dialysis who undergo colonoscopy: a retrospective multicentre study // BMC gastroenterology. 2019;19(1):175. https://doi.org/10.1186/s12876-019-1081-2.Fofi C., Festuccia F. Onconephrology: A New Challenge for the Nephrologist // Contrib Nephrol. – 2021. – Vol. 199. – P. 91–105. https://doi.org/10.1159/000517695. PMID: 34375977.Fofi C., Festuccia F. Onconephrology: A New Challenge for the Nephrologist // Contrib Nephrol. 2021;199:91–105. https://doi.org/10.1159/000517695. PMID: 34375977.Kitai Y., Matsubara T., Funakoshi T. et al. Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology // Renal Replacement Therapy. – 2016. – Vol. 2. – P. 1–9.Kitai Y., Matsubara T., Funakoshi T. et al. Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology // Renal Replacement Therapy. 2016;2:1–9.Bonilla M., Gudsoorkar P., Wanchoo R. et al. Onconephrology 2022: An Update // Kidney360. – 2023. – Vol. 4, № 2. – P. 258–271. https://doi.org/10.34067/KID.0001582022. PMID: 36821617; PMCID: PMC10103386.Bonilla M., Gudsoorkar P., Wanchoo R. et al. Onconephrology 2022: An Update // Kidney360. 2023;4(2):258–271. https://doi.org/10.34067/KID.0001582022. PMID: 36821617; PMCID: PMC10103386.de Rouw N., Piet B., Derijks H. J. et al. Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity // Drug Saf. – 2021. – Vol. 44, № 12. – P. 1271–1281. https://doi.org/10.1007/s40264-021-01135-2. PMID: 34741752.de Rouw N., Piet B., Derijks H. J. et al. Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity // Drug Saf. 2021;44(12):1271–1281. https://doi.org/10.1007/s40264-021-01135-2. PMID: 34741752.García-Carro C., Draibe J., Soler M. J. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity // Nephron. – 2023. – Vol. 147, № 2. – P. 65–77. https://doi.org/10.1159/000525029. PMID: 35717937.García-Carro C., Draibe J., Soler M. J. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity // Nephron. 2023;147(2):65–77. https://doi.org/10.1159/000525029. PMID: 35717937.Lanot A., Misery L., Rostoker G. et al. Diagnostic et prise en charge du prurit associé à la maladie rénale chronique chez les patients hémodialysés [Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients] // Nephrol Ther. – 2024. – Vol. 20, № 1. – P. 50–60. (In French). https://doi.org/10.1684/ndt.2024.60. PMID: 38294264.Lanot A., Misery L., Rostoker G. et al. Diagnostic et prise en charge du prurit associé à la maladie rénale chronique chez les patients hémodialysés [Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients] // Nephrol Ther. 2024;20(1):50–60. (In French). https://doi.org/10.1684/ndt.2024.60. PMID: 38294264.The North London cancer network. Dosage Adjustment for Cytotoxics in Renal Impairment. Jan. 2009. URL: www.londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf (accessed: 01.04.2025).The North London cancer network. Dosage Adjustment for Cytotoxics in Renal Impairment. Jan. 2009. URL: www.londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf (accessed: 01.04.2025).Smyth E. C., Nilsson M., Grabsch H. I. et al. Gastric cancer // Lancet (London, England). – 2020. – Vol. 396, № 10251. – P. 635–648. https://doi.org/10.1016/S0140-6736(20)31288-5.Smyth E. C., Nilsson M., Grabsch H. I. et al. Gastric cancer // Lancet (London, England). 2020;396(10251):635–648. https://doi.org/10.1016/S0140-6736(20)31288-5.Usui S., Tashiro M., Haruki S. et al. Spleen preservation versus splenectomy in laparoscopic total gastrectomy with D2 lymphadenectomy for gastric cancer: A comparison of short-term outcomes // Asian journal of endoscopic surgery. – 2016. – Vol. 9, № 1. – P. 5–13. https://doi.org/10.1111/ases.12255.Usui S., Tashiro M., Haruki S. et al. Spleen preservation versus splenectomy in laparoscopic total gastrectomy with D2 lymphadenectomy for gastric cancer: A comparison of short-term outcomes // Asian journal of endoscopic surgery. 2016;9(1):5–13. https://doi.org/10.1111/ases.12255.Symeonidis D., Diamantis A., Bompou E. et al. Current role of lymphadenectomy in gastric cancer surgery // Journal of B.U.ON: official journal of the Balkan Union of Oncology. – 2019. – Vol. 24, № 5. – P. 1761–1767.Symeonidis D., Diamantis A., Bompou E. et al. Current role of lymphadenectomy in gastric cancer surgery // Journal of B.U.ON: official journal of the Balkan Union of Oncology. 2019;24(5):1761–1767.Kotake K., Kobayashi H., Asano M. et al. Influence of extent of lymph node dissection on survival for patients with pT2 colon cancer // International journal of colorectal disease. – 2015. – Vol. 30, № 6. – P. 813–820. https://doi.org/10.1007/s00384-015-2194-x.Kotake K., Kobayashi H., Asano M. et al. Influence of extent of lymph node dissection on survival for patients with pT2 colon cancer // International journal of colorectal disease. 2015;30(6):813–820. https://doi.org/10.1007/s00384-015-2194-x.Brüggmann D., Tchartchian G., Wallwiener M. et al. Intra-abdominal adhesions: definition, origin, significance in surgical practice, and treatment options // Deutsches Arzteblatt international. – 2010. – Vol. 107, № 44. – P. 769–775. https://doi.org/10.3238/arztebl.2010.0769.Brüggmann D., Tchartchian G., Wallwiener M. et al. Intra-abdominal adhesions: definition, origin, significance in surgical practice, and treatment options // Deutsches Arzteblatt international. 2010;107(44):769–775. https://doi.org/10.3238/arztebl.2010.0769.Liu Y. Y., Tsai C. Y., Yeh C. N. et al. Gastric cancer patients with end-stage renal disease who underwent radical gastrectomy // Anticancer research. – 2015. – Vol. 35, № 4. – P. 2263–2268.Liu Y. Y., Tsai C. Y., Yeh C. N. et al. Gastric cancer patients with end-stage renal disease who underwent radical gastrectomy // Anticancer research. 2015;35(4):2263–2268.Супрунович К. С., Палтышев И. А., Захаренко А. А., Добронравов В. А. Онконефрология: острая болезнь почек после превентивной илеостомии у пациента с колоректальным раком // Нефрология. – 2023. – Т. 27, № 1. – С. 102–107. https://doi.org/10.36485/1561-6274-2023-27-1-102-107.Suprunovich K. S., Paltyshev I. A., Zakharenko A. A., Dobronravov V. A. Onconephrology: acute kidney disease after preventive ileostomy in a patient with colorectal cancer // Nephrology (Saint-Petersburg). 2023;27(1):102–107. (In Russ.). https://doi.org/10.36485/1561-6274-2023-27-1-102-107.Li L., Lau K. S., Ramanathan V. et al. Ileostomy creation in colorectal cancer surgery: risk of acute kidney injury and chronic kidney disease // J Surg Res. – 2017. – Vol. 210. – P. 204–212. https://doi.org/10.1016/j.jss.2016.11.039. PMID: 28457330.Li L., Lau K. S., Ramanathan V. et al. Ileostomy creation in colorectal cancer surgery: risk of acute kidney injury and chronic kidney disease // J Surg Res. 2017;210:204–212. https://doi.org/10.1016/j.jss.2016.11.039. PMID: 28457330.Borucki J. P., Schlaeger S., Crane J. et al. Risk and consequences of dehydration following colorectal cancer resection with diverting ileostomy. A systematic review and meta-analysis // Colorectal Dis. – 2021. – Vol. 23, № 7. – P. 1721–1732. https://doi.org/10.1111/codi.15654. PMID: 33783976.Borucki J. P., Schlaeger S., Crane J. et al. Risk and consequences of dehydration following colorectal cancer resection with diverting ileostomy. A systematic review and meta-analysis // Colorectal Dis. 2021;23(7):1721–1732. https://doi.org/10.1111/codi.15654. PMID: 33783976.Jazani N. H., Savoj J., Lustgarten M. et al. Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease // Diseases (Basel, Switzerland). 2019. – Vol. 7, № 1. – P. 21. https://doi.org/10.3390/diseases7010021.Jazani N. H., Savoj J., Lustgarten M. et al. Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease // Diseases (Basel, Switzerland). 2019;7(1):21. https://doi.org/10.3390/diseases7010021.Cernaro V., Coppolino G., Visconti L. et al. Erythropoiesis and chronic kidney disease-related anemia. – P. From physiology to new therapeutic advancements // Med Res Rev. – 2019. – Vol. 39, № 2. – P. 427–460. https://doi.org/10.1002/med.21527. PMID: 30084153.Cernaro V., Coppolino G., Visconti L. et al. Erythropoiesis and chronic kidney disease-related anemia: From physiology to new therapeutic advancements // Med Res Rev. 2019;39(2):427–460. https://doi.org/10.1002/med.21527. PMID: 30084153.Lee J. E., Han S. H., Cho B. C. et al. Cancer in patients on chronic dialysis in Korea // J Korean Med Sci. – 2009. – Vol. 24, № Suppl 1. – P. S95–S101. https://doi.org/10.3346/jkms.2009.24.S1.S95. PMID: 19194570; PMCID: PMC2633193.Lee J. E., Han S. H., Cho B. C. et al. Cancer in patients on chronic dialysis in Korea // J Korean Med Sci. 2009;24(Suppl 1):S95–S101. https://doi.org/10.3346/jkms.2009.24.S1.S95. PMID: 19194570; PMCID: PMC2633193.Chauveau P., Level C., Lasseur C. et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study // J Ren Nutr. – 2003. – Vol. 13, № 2. – P. 137–43. https://doi.org/10.1053/jren.2003.50017. PMID: 12671838.Chauveau P., Level C., Lasseur C. et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study // J Ren Nutr. 2003;13(2):137–43. https://doi.org/10.1053/jren.2003.50017. PMID: 12671838.Steinbach G., Bölke E., Grünert A. et al. Procalcitonin in patients with acute and chronic renal insufficiency // Wien Klin Wochenschr. – 2004. – Vol. 116, № 24. – P. 849–53. https://doi.org/10.1007/s00508-004-0279-6. Erratum in: Wien Klin Wochenschr. 2005. – Vol. 117, № 4. – P. 172. PMID: 15690970.Steinbach G., Bölke E., Grünert A. et al. Procalcitonin in patients with acute and chronic renal insufficiency // Wien Klin Wochenschr. 2004;116(24):849–53. https://doi.org/10.1007/s00508-004-0279-6. Erratum in: Wien Klin Wochenschr. 2005;117(4):172. PMID: 15690970.Azoulay E., Schellongowski P., Darmon M. et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients // Intensive Care Med. 2017. – Vol. 43, № 9. – P. 1366–1382. https://doi.org/10.1007/s00134-017-4884-z.Azoulay E., Schellongowski P., Darmon M. et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients // Intensive Care Med. 2017;43(9):1366–1382. https://doi.org/10.1007/s00134-017-4884-z.Pereira J. F., Pareek G., Mueller-Leonhard C. et al. The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement // Urology. – 2019. – Vol. 125. – P. 131–137. https://doi.org/10.1016/j.urology.2018.10.027. PMID: 30366045.Pereira J. F., Pareek G., Mueller-Leonhard C. et al. The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement // Urology. 2019;125:131–137. https://doi.org/10.1016/j.urology.2018.10.027. PMID: 30366045.Neki K., Takeda Y., Kosuge M. et al. Short-term Postoperative Outcomes of Colorectal Cancer Patients With Chronic Renal Failure on Dialysis // In Vivo. – 2022. – Vol. 36, № 5. – P. 2461–2464. https://doi.org/10.21873/invivo.12981. PMID: 36099108; PMCID: PMC9463909.Neki K., Takeda Y., Kosuge M. et al. Short-term Postoperative Outcomes of Colorectal Cancer Patients With Chronic Renal Failure on Dialysis // In Vivo. 2022;36(5):2461–2464. https://doi.org/10.21873/invivo.12981. PMID: 36099108; PMCID: PMC9463909.

The authors declare that there are no conflicts of interest present.